The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all‐cause mortality

Documenti analoghi

• Prevalence and impact of additional CHIP mutations in JAK2V617F‐positive ischaemic cerebrovascular patients
  di: Marie Hvelplund Kristiansen, et al.
  Pubblicazione: (2025)
• The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets
  di: Morten Orebo Holmström, et al.
  Pubblicazione: (2024)
• JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
  di: Christina Schjellerup Eickhardt‐Dalbøge, et al.
  Pubblicazione: (2024)
• Should Serum Transferrin Saturation Be Included as a Therapeutic Target in Addition to Serum Ferritin in Treating HFE ‐Hemochromatosis?
  di: Nils Thorm Milman, et al.
  Pubblicazione: (2025)
• Sustainability Discourses in the Leadership and Management Literature: A Critical Review
  di: Kristian Høyer Toft, et al.
  Pubblicazione: (2024)